APA (7th ed.) Citation

S, D., MV, M., HW, A., M, G., MA, D., H, Q., . . . S, G. (2022). Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. American journal of hematology, 97(3), E83. https://doi.org/10.1002/ajh.26434

Chicago Style (17th ed.) Citation

S, Delimpasi, et al. "Efficacy and Tolerability of Once-weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Standard Twice-weekly Bortezomib and Dexamethasone in Previously Treated Multiple Myeloma with Renal Impairment: Subgroup Analysis from the BOSTON Study." American Journal of Hematology 97, no. 3 (2022): E83. https://doi.org/10.1002/ajh.26434.

MLA (9th ed.) Citation

S, Delimpasi, et al. "Efficacy and Tolerability of Once-weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Standard Twice-weekly Bortezomib and Dexamethasone in Previously Treated Multiple Myeloma with Renal Impairment: Subgroup Analysis from the BOSTON Study." American Journal of Hematology, vol. 97, no. 3, 2022, p. E83, https://doi.org/10.1002/ajh.26434.